Biblio

Export 119 results:
[ Author(Desc)] Title Type Year
Filters: Keyword is tau Proteins  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
B. Ahlemeyer, Halupczok, S., Rodenberg-Frank, E., Valerius, K. - P., and Baumgart-Vogt, E., “Endogenous Murine Amyloid-β Peptide Assembles into Aggregates in the Aged C57BL/6J Mouse Suggesting These Animals as a Model to Study Pathogenesis of Amyloid-β Plaque Formation.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1425-1450, 2018.
H. B. Allen, “A Novel Approach to the Treatment and Prevention of Alzheimer's Disease Based on the Pathology and Microbiology.”, J Alzheimers Dis, vol. 84, no. 1, pp. 61-67, 2021.
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
Á
I. Álvarez, Aguilar, M., González, J. Manuel, Ysamat, M., Lorenzo-Bosquet, C., Alonso, A., Tartari, J. Pablo, Romero, S., Diez-Fairen, M., Carcel, M., Pujalte, F., and Pastor, P., “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
A
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
A. Arner, Rockenstein, E., Mante, M., Florio, J., Masliah, D., Salehi, B., Adame, A., Overk, C., Masliah, E., and Rissman, R. A., “Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1201-1219, 2018.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
B
L. García Barrado, Coart, E., Vanderstichele, H. M. J., and Burzykowski, T., “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
N. R. Barthélemy, Gabelle, A., Hirtz, C., Fenaille, F., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Junot, C., Becher, F., and Lehmann, S., “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
R. Beardmore, Hou, R., Darekar, A., Holmes, C., and Boche, D., “The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review.”, J Alzheimers Dis, vol. 83, no. 1, pp. 5-22, 2021.
J. Bennett, Burns, J., Welch, P., and Bothwell, R., “Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
G. Berge, Lauridsen, C., Sando, S. Botne, Holder, D. Joseph, Møller, I., Aasly, J. Olav, Bråthen, G., Savage, M. Josephine, and White, L. Rosemary, “Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.”, J Alzheimers Dis, vol. 49, no. 2, pp. 493-502, 2016.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
M. Bolós, Llorens-Martín, M., Jurado-Arjona, J., Hernández, F., Rábano, A., and Avila, J., “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
C. Giuseppina Bonomi, Assogna, M., Di Donna, M. Gaia, Bernocchi, F., De Lucia, V., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. Biagio, Koch, G., Martorana, A., and Motta, C., “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
G. Boström, Freyhult, E., Virhammar, J., Alcolea, D., Tumani, H., Otto, M., Brundin, R. - M., Kilander, L., Löwenmark, M., Giedraitis, V., Lleo, A., von Arnim, C. A. F., Kultima, K., and Ingelsson, M., “Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 81, no. 2, pp. 629-640, 2021.
O. Bousiges, Cretin, B., Lavaux, T., Philippi, N., Jung, B., Hezard, S., Heitz, C., Demuynck, C., Gabel, A., Martin-Hunyadi, C., and Blanc, F., “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
H. Braak, Thal, D. R., Ghebremedhin, E., and Del Tredici, K., “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
D. Brici, Götz, J., and Nisbet, R. M., “A Novel Antibody Targeting Tau Phosphorylated at Serine 235 Detects Neurofibrillary Tangles.”, J Alzheimers Dis, vol. 61, no. 3, pp. 899-905, 2018.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
C
L. Calderón-Garcidueñas, Kavanaugh, M., Block, M., D'Angiulli, A., Delgado-Chávez, R., Torres-Jardón, R., González-Maciel, A., Reynoso-Robles, R., Osnaya, N., Villarreal-Calderon, R., Guo, R., Hua, Z., Zhu, H., Perry, G., and Diaz, P., “Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.”, J Alzheimers Dis, vol. 28, no. 1, pp. 93-107, 2012.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
P. Chatterjee, Doré, V., Pedrini, S., Krishnadas, N., Thota, R., Bourgeat, P., Ikonomovic, M. D., Rainey-Smith, S. R., Burnham, S. C., Fowler, C., Taddei, K., Mulligan, R., Ames, D., Masters, C. L., Fripp, J., Rowe, C. C., Martins, R. N., and Villemagne, V. L., “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
S. Hoon Choi, Kim, Y. Hye, Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., and Kim, D. Yeon, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.

Pages